| Bioactivity | BIHC is a Her2-CD3 bispecific antibody constructed from a single-domain antibody targeting Her2 and a single-chain variable fragment (Fv) targeting CD3, formatted in an IgG-like structure. BIHC demonstrates effective antitumor activity in vivo, specifically binding to tumor cells expressing Her2 and efficiently eliminating Her2-positive cancer cells by recruiting T cells, thus being used in the study of Her2-positive cancers[1]. |
| CAS | 1642826-40-1 |
| Formula | C26H21ClN2O6 |
| Molar Mass | 492.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xing J, et al. BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells. Transl Oncol. 2017 Oct;10(5):780-785. |